ArticleMolecular oncology2008
Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate.
Article in Molecular oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Trial
- Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis.Endocrine-related cancer · 2024Article
- Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations.Drugs in R&D · 2024Review
- Identification of significant gene expression changes in multiple perturbation experiments using knockoffs.Briefings in bioinformatics · 2023Article
- Article
- Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies.Current treatment options in oncology · 2022Review
- Article
- N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC.Cancer science · 2021Article
- Article
- Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.Scientific reports · 2019Article
- Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.Steroids · 2018Review
- Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer.Journal of Cancer · 2018Article
- Article
- MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.Endocrine-related cancer · 2016Article
- Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells.Oncotarget · 2016Article
- Growth and repair factors, osteoactivin, matrix metalloproteinase and heat shock protein 72, increase with resolution of inflammation in musculotendinous tissues in a rat model of repetitive grasping.BMC musculoskeletal disorders · 2016Article
- Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.Cancer medicine · 2015Article
- Immunolocalization of dually phosphorylated MAPKs in dividing root meristem cells of Vicia faba, Pisum sativum, Lupinus luteus and Lycopersicon esculentum.Plant cell reports · 2015Article
- The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.Cell communication and signaling : CCS · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GPNMB is a melanoma-associated glycoprotein that is targeted by the CR011-vcMMAE antibody-drug conjugate (ADC). Previous studies have shown that CR011-vcMMAE induces the apoptosis of GPNMB-expressing tumor cells in vitro and tumor regression in xenograft models. This ADC is currently in clinical trials for melanoma. In the present investigation, a variety of compounds were examined for their ability to increase the expression of GPNMB by cancer cells. These experiments lead to the identification of three distinct groups of compounds that increased GPNMB, some of which were shown to enhance the sensitivity of melanoma cells to CR011-vcMMAE. These data indicate that it may be possible to increase the anticancer activity of CR011-vcMMAE through pharmacological enhancement of GPNMB expression for potential therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.